Attorneys general from several states had accused Lilly of marketing the drug for pediatric care, for use at a high dose and for the treatment of dementia. The company also was accused of inadequately disclosing the drug's side effects to health care providers.
The company did not admit wrongdoing in the settlement.
The money is to be distributed to 32 states and the District of Columbia based on their populations.
